Ask AI
ProCE Banner Activity

Thoughts on Emerging PROTAC ER Degraders for Patients With Advanced HR+/HER2- Metastatic Breast Cancer

Clinical Thought

Read this commentary for expert insights on emerging data for PROTAC ER degraders in patients with HR-positive/HER2-negative metastatic breast cancer addressing an unmet need in patients with ESR1-mutated cancers after progression on ET and CDK4/6 inhibitor.

Released: October 01, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Pfizer, Inc. and Arvinas.

Arvinas

Pfizer, Inc.

Disclosure

Primary Author

Rita Nanda, MD: advisor: Arvinas, AstraZeneca, Daiichi Sankyo, Exact Sciences, GE, Gilead, Guardant Health, Lilly, Merck, Moderna, Novartis, OBI, Pfizer, Sanofi, Seagen, Stemline, Summit; researcher: Arvinas, AstraZeneca, Bristol Myers Squibb, Corcept, Genentech/Roche, Gilead, GSK, Merck, Novartis, OBI Pharma, Pfizer, Relay, Seattle Genetics, Sun, Taiho.